Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Therapeutics to Present at September 2024 Investor Conferences

August 28, 2024
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 21, 2024
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

August 12, 2024
Chemomab Therapeutics Announces Closing of $10 Million Private Placement

July 30, 2024
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

July 26, 2024
Chemomab Therapeutics Announces $10 Million Private Placement

July 25, 2024
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

July 25, 2024

First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated
- Photos 2
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

June 18, 2024
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

June 06, 2024
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 17, 2024